RT @NatureOutlook: The race to develop treatments for what has become the most prevalent form of chronic liver disease. #NAFLD @liamjdrew h…
RT @NatureOutlook: The race to develop treatments for what has become the most prevalent form of chronic liver disease. #NAFLD @liamjdrew h…
The race to develop treatments for what has become the most prevalent form of chronic liver disease. #NAFLD @liamjdrew https://t.co/XS9jLjTE4m
RT @_unit76: #HEMO buyout, JV or takeover? 🤔 https://t.co/D2yxBcy2rg
#HEMO buyout, JV or takeover? 🤔 https://t.co/D2yxBcy2rg
RT @HemoGenyx: A biotech startup does not even have to be in clinical trials to be valued and acquired for hundreds of millions @HemoGenyx.…
RT @HemoGenyx: A biotech startup does not even have to be in clinical trials to be valued and acquired for hundreds of millions @HemoGenyx.…
RT @HemoGenyx: A biotech startup does not even have to be in clinical trials to be valued and acquired for hundreds of millions @HemoGenyx.…
RT @NatureOutlook: Suddenly, pharma companies are pouring millions of dollars into treatments for fatty liver disease, by @liamjdrew. https…
RT @NatureOutlook: Suddenly, pharma companies are pouring millions of dollars into treatments for fatty liver disease, by @liamjdrew. https…
RT @NatureOutlook: Suddenly, pharma companies are pouring millions of dollars into treatments for fatty liver disease, by @liamjdrew. https…
Suddenly, pharma companies are pouring millions of dollars into treatments for fatty liver disease, by @liamjdrew. https://t.co/XS9jLjC2FM
RT @NatureOutlook: There are currently more than 200 active trials of treatments for nonalcoholic fatty liver disease (#NAFLD). Which will…
There are currently more than 200 active trials of treatments for nonalcoholic fatty liver disease (#NAFLD). Which will prevail @liamjdrew https://t.co/XS9jLjTE4m
After decades of development, drugs for treating nonalcoholic fatty liver disease are racing towards the clinic #NAFLD #NASH https://t.co/XS9jLjTE4m
RT @LITMUS_IMI: Many researchers within the LITMUS project are mentioned in this Nature Outlook article. https://t.co/QcRXQRKWay In LITMUS,…
RT @LITMUS_IMI: Many researchers within the LITMUS project are mentioned in this Nature Outlook article. https://t.co/QcRXQRKWay In LITMUS,…
RT @LITMUS_IMI: Many researchers within the LITMUS project are mentioned in this Nature Outlook article. https://t.co/QcRXQRKWay In LITMUS,…
RT @LITMUS_IMI: Many researchers within the LITMUS project are mentioned in this Nature Outlook article. https://t.co/QcRXQRKWay In LITMUS,…
RT @LITMUS_IMI: Many researchers within the LITMUS project are mentioned in this Nature Outlook article. https://t.co/QcRXQRKWay In LITMUS,…
RT @LITMUS_IMI: Many researchers within the LITMUS project are mentioned in this Nature Outlook article. https://t.co/QcRXQRKWay In LITMUS,…
RT @Adrian_YH_Lin: Drug development: Sprint finish https://t.co/K8x1nro8xw
Many researchers within the LITMUS project are mentioned in this Nature Outlook article. https://t.co/QcRXQRKWay In LITMUS, we are developing and validating biomarkers for NASH which can enable more effective medical treatments. @IMI_JU @EFPIA
RT @Adrian_YH_Lin: Drug development: Sprint finish https://t.co/K8x1nro8xw
Drug development: Sprint finish https://t.co/K8x1nro8xw
The rush is on to develop drugs for fatty liver disease, reports @liamjdrew. #NAFLD https://t.co/XS9jLjTE4m
RT @NatureOutlook: The race is on to find a cure for fatty liver disease, writes @liamjdrew. https://t.co/XS9jLjC2FM
RT @NatureOutlook: The race is on to find a cure for fatty liver disease, writes @liamjdrew. https://t.co/XS9jLjC2FM
RT @NatureOutlook: The race is on to find a cure for fatty liver disease, writes @liamjdrew. https://t.co/XS9jLjC2FM
The race is on to find a cure for fatty liver disease, writes @liamjdrew. https://t.co/XS9jLjC2FM
Therapy = Crosby... Geddit? #owningthepun https://t.co/5umUEek211
Therapy, pills and NASH: New treatments for fatty liver disease could arrive soon, reports @liamjdrew. #NAFLD #NASH https://t.co/XS9jLjTE4m
RT @HemoGenyx: A biotech startup does not even have to be in clinical trials to be valued and acquired for hundreds of millions @HemoGenyx.…
RT @missthepenny62: Not only is #HEMO potentially life changing because everyone hates chemo and it should make a huge difference, it is al…
RT @NatureOutlook: The race is on to develop therapies for non-alcoholic fatty liver disease. https://t.co/XS9jLjTE4m. @liamjdrew has our r…
RT @YVR_Trader: When it comes to treating #NASH $CWBR will have its say when all is said and done. https://t.co/4HHEBZfOLo
There's a sprint on to develop drugs to treat non-alcoholic fatty liver disease. Why not try simple dietray changes first? My n=1 says it work quickly, at least for some. https://t.co/I8hrlHeuj4
RT @HemoGenyx: A biotech startup does not even have to be in clinical trials to be valued and acquired for hundreds of millions @HemoGenyx.…
RT @missthepenny62: Not only is #HEMO potentially life changing because everyone hates chemo and it should make a huge difference, it is al…
When it comes to treating #NASH $CWBR will have its say when all is said and done. https://t.co/4HHEBZfOLo
RT @HemoGenyx: A biotech startup does not even have to be in clinical trials to be valued and acquired for hundreds of millions @HemoGenyx.…
Not only is #HEMO potentially life changing because everyone hates chemo and it should make a huge difference, it is also a potentially life changing investment because the upside is almost 'off the scale'. Win-Win. https://t.co/LXTFbzBhgH
RT @HemoGenyx: A biotech startup does not even have to be in clinical trials to be valued and acquired for hundreds of millions @HemoGenyx.…
RT @HemoGenyx: A biotech startup does not even have to be in clinical trials to be valued and acquired for hundreds of millions @HemoGenyx.…
RT @HemoGenyx: A biotech startup does not even have to be in clinical trials to be valued and acquired for hundreds of millions @HemoGenyx.…
RT @NatureOutlook: The race is on to develop therapies for non-alcoholic fatty liver disease. https://t.co/XS9jLjTE4m. @liamjdrew has our r…
RT @HemoGenyx: A biotech startup does not even have to be in clinical trials to be valued and acquired for hundreds of millions @HemoGenyx.…
RT @HemoGenyx: A biotech startup does not even have to be in clinical trials to be valued and acquired for hundreds of millions @HemoGenyx.…
RT @HemoGenyx: A biotech startup does not even have to be in clinical trials to be valued and acquired for hundreds of millions @HemoGenyx.…
A biotech startup does not even have to be in clinical trials to be valued and acquired for hundreds of millions @HemoGenyx. https://t.co/fbArYfjKZa
Tens of companies, scores of drugs and hundreds of trials... My take on the clamber to develop new therapies for NA fatty liver disease. https://t.co/2lSIAE9VcW
The race is on to develop therapies for non-alcoholic fatty liver disease. https://t.co/XS9jLjTE4m. @liamjdrew has our roundup on the competition. #NAFLD #NASH https://t.co/2yZSxGHrKE
Drug development: Sprint finish https://t.co/0LXylVdbKM